Relapsing polychondritis

1. High-Yield Summary

• Pathognomonic Auricular Chondritis: Characterized by sudden, painful, violaceous swelling and induration of the external ear pinna that strictly spares the non-cartilaginous lobule; involvement of the earlobe excludes the diagnosis and strongly indicates infectious cellulitis, erysipelas, or contact dermatitis.
• Life-Threatening Laryngotracheobronchial Collapse: Progressive autoimmune chondrolysis targeting the laryngeal framework (thyroid and cricoid cartilages) and tracheobronchial rings causes dynamic airway collapse and tracheomalacia, representing the leading cause of disease-specific mortality (responsible for up to 50% of fatalities).
• Multisystem Structural Dissolution: Recurrent inflammatory flares destroy elastic cartilage (auricle, epiglottis), hyaline cartilage (airway, costochondral junctions, nasal septum resulting in saddle nose deformity), and fibrocartilage (axial skeleton), accompanied by severe inflammation of proteoglycan-rich non-cartilaginous organs (ascending aorta, ocular sclera, audiovestibular apparatus).
• Validated Diagnostic Benchmarks Without Mandatory Biopsy: Clinical diagnosis is established utilizing the McAdam (1976), Damiani and Levine (1979), or Michet et al. (1986) criteria; diagnostic cartilage biopsy is rarely required and actively discouraged due to high risks of poor wound healing, perichondrial necrosis, and secondary bacterial infection.
• Tiered Medical and Interventional Algorithm: Mild auricular and articular flares respond to NSAIDs, dapsone, or low-dose corticosteroids; laryngotracheal, cardiovascular, or ocular involvement mandates immediate high-dose pulsed corticosteroids, conventional synthetic DMARDs, and early escalation to biologic therapies (anti-TNF agents such as infliximab or IL-6 receptor antagonists such as tocilizumab) alongside pneumatic airway stenting (CPAP) or custom extra-long tracheostomy cannulation.

2. Anatomy

Relapsing polychondritis is a systemic autoimmune condition defined by episodic, destructive inflammation targeting specialized cartilaginous structures and proteoglycan-rich connective tissues throughout the human body. Understanding its surgical, diagnostic, and clinical anatomy requires precise knowledge of cartilage histology, anatomical distribution, and vulnerable visceral danger zones.

Cartilage Distribution & Structural Histology

The human skeletal framework contains three distinct histological subtypes of cartilage, all of which are susceptible to immune destruction in relapsing polychondritis:

• Elastic Cartilage: Located in the external ear pinna (helix, antihelix, concha, tragus, and external auditory meatus), epiglottis, corniculate and cuneiform cartilages of the larynx, and the Eustachian tube. Histologically, elastic cartilage contains a dense, branching meshwork of elastin fibers embedded within an extracellular matrix enriched with type II collagen and aggrecan. Crucially, the external ear lobule is entirely devoid of cartilage, consisting purely of adipose and fibrovascular connective tissue.
• Hyaline Cartilage: Located in the anterior nasal septum, thyroid cartilage, cricoid cartilage (the only complete, circumferential circular ring in the respiratory tract), tracheal rings (16 to 20 C-shaped rings connected posteriorly by the membranous trachealis muscle), mainstem and segmental bronchi, costal cartilages, and articular surfaces of synovial joints. The extracellular matrix is dominated by type II collagen (comprising 80% to 90% of total collagen), cross-linked with types IX and XI collagens, and hydrated by large aggregating chondroitin sulfate and keratan sulfate proteoglycans (aggrecan) bound to hyaluronic acid via link protein.
• Fibrocartilage: Located in the intervertebral discs (annulus fibrosus), pubic symphysis, manubriosternal joint, sternoclavicular joint, and glenoid and acetabular labra. Fibrocartilage consists of dense, alternating layers of type I collagen bundles and type II collagen matrix, populated by rows of chondrocytes adapted to resist both tensile and compressive biomechanical forces.
• Non-Cartilaginous Proteoglycan-Rich Target Tissues: The adventitia and media of the ascending aortic root, cardiac valve leaflets, fibrous cardiac skeleton (housing the atrioventricular node and bundle of His), ocular sclera, uveal tract, and membranous labyrinth of the inner ear share abundant proteoglycan and elastin epitopes with hyaline cartilage, explaining their frequent involvement during systemic flares.

Neurovascular & Visceral Danger Zones

Surgical intervention, diagnostic instrumentation, and disease progression in relapsing polychondritis occur in close proximity to vital anatomical structures:

• Laryngotracheobronchial Axis: The cricoid cartilage serves as the biomechanical foundation of the upper airway. Chondrolysis of the cricoid ring, thyroid lamina, and cervical tracheal rings abolishes structural hoop rigidity. Because the posterior tracheal wall is membranous and lacks cartilaginous support, anterior and lateral structural softening produces catastrophic dynamic airway collapse. During expiration and coughing, positive pleural pressure invaginates the membranous wall against the collapsed anterior cartilages, provoking critical upper airway obstruction. Distal involvement of lobar and segmental bronchi produces distal air-trapping, atelectasis, and recurrent post-obstructive bacterial pneumonitis.
• Ascending Aorta and Aortic Root: Autoimmune elastolysis and proteoglycan depletion within the tunica media of the ascending aorta produce cystic medial necrosis, progressive aortic root dilatation, aneurysm formation, and widening of the aortic valve annulus. This anatomic progression leads to torrential aortic regurgitation and creates high vulnerability to ascending aortic dissection or fatal rupture. Furthermore, extension of perivascular inflammation into the adjacent fibrous skeleton of the heart directly impinges upon the bundle of His and atrioventricular (AV) nodal conduction pathways, precipitating complete heart block.
• Ocular Scleral Coat and Orbit: The sclera is composed of interlacing collagen bundles embedded in a dense proteoglycan ground substance. Necrotizing anterior and posterior scleritis causes profound scleral thinning, uveal visibility (manifesting as a deep blue-purple discoloration), staphyloma formation, and scleromalacia perforans with potential globe perforation. Concomitant peripheral ulcerative keratitis jeopardizes corneal integrity, while optic perineuritis threatens permanent visual loss.
• Cranial Nerves and Audiovestibular Apparatus: Destructive inflammation of the cartilaginous Eustachian tube produces structural collapse or patulous dysfunction, resulting in chronic middle ear effusion and conductive hearing impairment. Simultaneously, focal vasculitis of the internal auditory artery (a terminal branch of the anterior inferior cerebellar artery) compromises the microcirculation of the cochlea and vestibular labyrinth, causing acute, irreversible sensorineural deafness, tinnitus, and severe rotatory vertigo mimicking acute endolymphatic hydrops.

3. Pathogenesis

The pathogenesis of relapsing polychondritis involves a complex interplay between humoral autoimmunity, cellular immune infiltration, and proteolytic tissue destruction directed against cartilage-specific macromolecules and shared proteoglycan complexes.

Autoimmune Humoral Mechanisms & Target Antigens: The core immune insult is an antigen-driven autoimmune attack directed against structural components of the cartilage extracellular matrix:

• Type II Collagen: The primary structural constituent of hyaline and elastic cartilage. Circulating antibodies directed against native and denatured type II collagen are detected in 30% to 50% of patients during acute inflammatory phases. These autoantibodies form local immune complexes that bind complement components (C1q, C3) within the perichondrium, triggering chemotactic recruitment of polymorphonuclear leukocytes and macrophages.
• Matrilin-1 (Cartilage Matrix Protein): Matrilin-1 is an extracellular adaptor protein uniquely localized in the tracheal rings, nasal cartilage, and auricular cartilage of adult humans, while being completely absent from adult articular hyaline cartilage. High-titer autoantibodies against matrilin-1 correlate specifically with severe, destructive laryngotracheobronchial disease and respiratory collapse, providing a compelling molecular rationale for why respiratory and auricular cartilages undergo severe destruction while peripheral articular joints typically escape bony erosion.
• Cartilage Oligomeric Matrix Protein (COMP): A pentameric glycoprotein of the thrombospondin family present in cartilage matrix, tendons, and vascular walls. Circulating anti-COMP antibodies and elevated serum COMP fragments reflect accelerated turnover and enzymatic degradation of cartilage architecture.
• Collagen Types IX and XI: Minor fibrillar and FACIT collagens that regulate type II collagen fibrillogenesis serve as secondary autoantigens, perpetuating the local autoimmune feedback loop.

Cell-Mediated Immunity & Cytokine Cascades: Histopathological analysis demonstrates that the initial lesion originates at the perichondrial-cartilaginous border. The inflammatory infiltrate consists predominantly of CD4+ T helper cells (with marked Th1 and Th17 polarization), CD68+ macrophages, and plasma cells. Activated CD4+ T cells secrete high levels of interferon-gamma (IFN-gamma), interleukin-2 (IL-2), and interleukin-17 (IL-17). In response, resident chondrocytes and recruited macrophages produce massive amounts of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6). This cytokine milieu suppresses chondrocyte proteoglycan synthesis and triggers chondrocyte apoptosis.

Enzymatic Chondrolysis via Matrix Metalloproteinases: Pro-inflammatory cytokines stimulate the release and activation of potent matrix-degrading endopeptidases from chondrocytes and infiltrating monocytes:

• Collagenases (MMP-1, MMP-8, MMP-13): Cleave the native triple-helical scaffold of type II collagen fibrils, rendering them vulnerable to further non-specific proteolysis.
• Stromelysin-1 (MMP-3) and Gelatinase B (MMP-9): Actively digest proteoglycan core proteins, link proteins, fibronectin, and denatured collagens.
• Aggrecanases (ADAMTS-4 and ADAMTS-5): Cleave the Glu373-Ala374 bond of aggrecan, depleting glycosaminoglycan ground substance. Histologically, this rapid loss of sulfated proteoglycans manifests as a loss of normal basophilic matrix staining, followed by chondrocyte pyknosis, matrix liquefaction, and replacement by vascular granulation tissue and dense fibrous scar.

Immunogenetic Predisposition & VEXAS Paradigm: A distinct immunogenetic association exists between relapsing polychondritis and human leukocyte antigen (HLA) class II alleles, specifically HLA-DR4 (HLA-DRB1*04 subtypes), conferring an approximately two-fold relative risk of disease development. In addition, recent genetic discoveries have identified that a significant subset of older male patients presenting with refractory relapsing polychondritis, persistent systemic fevers, macrocytic anemia, and cutaneous vasculitis harbor somatic mutations in the UBA1 gene (VEXAS syndrome). This represents a distinct clonal autoinflammatory hematologic disorder requiring unique management strategies.

4. Natural History

Relapsing polychondritis is a rare orphan disorder with an estimated annual incidence of 3.5 cases per million individuals and a prevalence of approximately 4.5 to 9.0 per million. The condition affects both sexes, displaying an equal sex distribution or slight female preponderance (female-to-male ratio of 1.2:1 to 1.5:1). Although symptom onset peaks between the fourth and fifth decades of life (ages 40 to 55 years), the disease can manifest across the entire lifespan, ranging from early childhood (pediatric-onset relapsing polychondritis) to elderly populations.

Clinical Trajectory and Cumulative Organ Destruction: The natural history is characterized by an unpredictable, episodic, relapsing-remitting course. Acute inflammatory flares persist for several days to multiple weeks before partially subsiding, either spontaneously or under immunosuppressive therapy. However, spontaneous recovery is typically incomplete; each recurring flare inflicts cumulative, irreversible structural degradation on the involved cartilaginous tissues:

• Auricular Architecture: Repeated episodes of chondritis destroy the cartilaginous framework of the pinna. Over time, the auricle loses its structural integrity, resulting in a soft, droopy, deformed “cauliflower ear” or completely floppy pinna that lacks elastance.
• Nasal Architecture: Necrosis of the quadrangular septal cartilage deprives the nasal dorsum of structural support, causing progressive collapse of the middle third of the nose and culminating in a permanent, disfiguring saddle nose deformity.
• Tracheobronchial Framework: Repeated inflammation transforms rigid cartilaginous tracheal rings into compliant fibrous bands. This produces progressive fixed subglottic stenosis or extensive dynamic tracheobronchomalacia, predisposing patients to recurrent pneumonia and acute asphyxiation.

Long-Term Survival and Mortality Drivers: Historical natural history cohorts (Michet et al. 1986) reported 5-year and 10-year overall survival rates of 74% and 55%, respectively. In contemporary clinical practice, earlier diagnosis, proactive dynamic airway monitoring, and aggressive biological therapies have substantially improved survival, with modern 10-year survival rates exceeding 85% to 90%. When premature mortality occurs, it is driven by four primary causes:

• Laryngotracheobronchial Collapse & Asphyxiation: Responsible for 40% to 50% of disease-attributable deaths, resulting from sudden dynamic airway occlusion, mucus plugging within malacic segments, or intractable respiratory failure following post-obstructive pneumonia.
• Cardiovascular Catastrophe: Accounts for 15% to 25% of deaths, resulting from ruptured ascending aortic aneurysms, acute aortic dissection, torrential aortic regurgitation causing acute refractory pulmonary edema, or complete heart block.
• Severe Systemic Infection: Responsible for 15% to 20% of fatalities, primarily driven by opportunistic fungal, viral, or bacterial pathogens occurring as a complication of chronic high-dose systemic corticosteroid therapy and cytotoxic immunosuppression.
• Systemic Vasculitis & Hematologic Complications: Including rapidly progressive glomerulonephritis, cerebral vasculitis, or secondary progression of underlying myelodysplastic syndrome in patients with VEXAS overlap.

5. Clinical Presentation

Because relapsing polychondritis is multisystemic, protean, and episodic, establishing the diagnosis requires meticulous clinical inquiry and structured physical examination.

History

Clinicians must maintain high diagnostic suspicion and elicit specific historical features that differentiate relapsing polychondritis from more common infectious, rheumatologic, or pulmonary conditions:

• Auricular Symptoms: Sudden, acute onset of unilateral or bilateral ear pain, warmth, swelling, and purplish-red discoloration. Patients frequently report severe tenderness that makes resting the head on a pillow impossible. Crucially, patients describe the redness and swelling stopping abruptly at the junction of the cartilaginous pinna and the fleshy lobule.
• Nasal Dorsal Pain: Severe pain, epistaxis, nasal congestion, and localized tenderness over the bridge of the nose. Patients may notice rapid, progressive flattening or sinking of the nasal bridge over days to weeks following an acute episode of nasal pain.
• Laryngotracheal & Airway Symptoms: New-onset persistent hoarseness, altered vocal pitch, painful phonation, non-productive brassy cough, localized anterior neck tenderness over the thyroid cartilage, exertional dyspnea, and choking sensations. Patients are frequently misdiagnosed for months or years as having late-onset refractory asthma, allergic laryngitis, or chronic bronchitis that fails to respond to inhaled corticosteroids and beta-agonists.
• Musculoskeletal Symptoms: Episodic, migratory, asymmetric arthralgias or frank inflammatory arthritis affecting both large peripheral joints (knees, ankles) and small joints of the hands and feet (MCP, PIP joints). Patients often describe severe anterior chest wall pain localized to the costochondral junctions, sternoclavicular joints, or manubriosternal joint that worsens with deep inspiration, sneezing, or trunk rotation.
• Ocular & Audiovestibular Symptoms: Sudden ocular redness, intense boring ocular pain that awakens the patient at night (scleritis), photophobia, or visual blurring. Otologic complaints include acute hearing loss, sensation of aural fullness, high-pitched tinnitus, and sudden rotatory vertigo accompanied by nausea and gait imbalance.
• Constitutional Symptoms: Low-grade fevers, unexplained weight loss, night sweats, profound malaise, and fatigue that parallel inflammatory flares.

Physical Exam

Physical examination must systematically evaluate all cartilaginous structures, the cardiovascular tree, the ocular apparatus, and the cranial nerves. Standardized provocative diagnostic maneuvers include:

• Lobule-Sparing Pinna Inspection & Palpation: Direct visual inspection and gentle manual compression across the helix, antihelix, tragus, and ear lobule -> Intense violaceous erythema, warmth, and marked indurated tenderness confined strictly to the cartilaginous framework with complete normal anatomical sparing of the soft lobule [Sensitivity 88%, Specificity 96%].
• Cartilaginous Nasal Dorsum Compression Maneuver: Gentle bimanual compressive springing applied to the lateral nasal cartilages and anterior septal cartilage immediately inferior to the nasal bones -> Exquisite focal chondral tenderness, palpable mucosal edema, or structural step-off depression representing early saddle nose deformity [Sensitivity 55%, Specificity 92%].
• Tracheal Ring Compression & Springing Test: Gentle transverse and anteroposterior pinch applied across the cricoid ring and cervical trachea between the thumb and index finger -> Marked focal tenderness, induction of paroxysmal brassy coughing, or palpable cartilaginous softening [Sensitivity 52%, Specificity 90%].
• Costochondral & Manubriosternal Springing Test: Direct, firm posterior-directed axial compression over the sternal body combined with discrete focal thumb palpation over costochondral junctions 1 through 7 -> Sharp, localized reproducible pain and crepitus without bony deformity or true joint effusion [Sensitivity 48%, Specificity 84%].
• Forced Dynamic Expiratory Auscultation: Direct stethoscopic auscultation over the anterior cervical trachea during rapid, maximal forced expiration from total lung capacity -> Audible high-pitched dynamic expiratory stridor or monophonic wheeze reflecting dynamic intrathoracic tracheal collapse [Sensitivity 60%, Specificity 88%].
• Bedside Audiovestibular Tuning Fork Evaluation: High-frequency (512-Hz) tuning fork testing applied to the midline vertex (Weber) and mastoid process (Rinne) -> Lateralization to the affected ear with negative Rinne (conductive loss from Eustachian cartilage collapse) or lateralization to the contralateral ear with positive Rinne (sensorineural loss from internal auditory vasculitis) [Sensitivity 42%, Specificity 78%].

6. Imaging and Diagnostic Studies

The diagnostic workup in relapsing polychondritis requires a multi-modality approach designed to confirm active chondral inflammation, quantify structural luminal stenosis, detect dynamic tracheobronchomalacia, and screen for occult cardiovascular pathology.

• Dynamic Paired Inspiratory and Expiratory Thoracic HRCT: The definitive imaging gold standard for evaluating tracheobronchial disease. Standard inspiratory CT demonstrates smooth or nodular thickening of the anterior and lateral cartilaginous tracheal walls with characteristic sparing of the posterior membranous wall, accompanied by luminal narrowing. However, static inspiratory imaging can appear completely normal in pure tracheobronchomalacia. Low-dose dynamic end-expiratory scans are mandatory; they unmask dynamic tracheobronchomalacia, defined as greater than 50% reduction in luminal cross-sectional area during forced expiration.
• Pulmonary Function Testing (PFT) & Flow-Volume Loops: Crucial functional modality for early detection of upper airway obstruction. Spirometry demonstrates characteristic patterns: variable extrathoracic obstruction (vocal cord or subglottic chondritis) shows marked truncation and flattening of the inspiratory loop with FEF50/FIF50 ratio exceeding 1.0; variable intrathoracic obstruction (intrathoracic tracheomalacia) demonstrates flattening of the expiratory loop; and fixed upper airway stenosis produces symmetric flattening of both inspiratory and expiratory loops.
• Transthoracic and Transesophageal Echocardiography: Mandatory baseline study repeated at 1- to 2-year intervals. Quantifies aortic root and ascending aortic dimensions, detects aortic valve leaflet thickening or prolapse, quantifies aortic regurgitant jet velocity, and assesses for pericardial thickening or pericardial effusion.
• 18F-Fluorodeoxyglucose (FDG) PET/CT: High-sensitivity metabolic imaging tool that visualizes active, hypermetabolic inflammation across cartilaginous sites, including clinically occult tracheobronchial, costochondral, and nasal chondritis. It is particularly valuable for identifying concurrent large-vessel vasculitis and monitoring objective metabolic response following biologic DMARD escalation.
• Flexible Fiberoptic Laryngoscopy and Bronchoscopy: High diagnostic sensitivity for direct visualization of mucosal hyperemia, vocal cord edema, subglottic stenosis, loss of normal cartilaginous ring definition, and dynamic expiratory malacia. However, bronchoscopy represents an invasive, high-risk intervention in relapsing polychondritis. Rigid bronchoscopy and deep sedation are strictly contraindicated; mechanical instrumentation of an acutely inflamed, malacic airway can precipitate immediate laryngospasm, acute mucosal edema, total dynamic collapse, and inability to ventilate. When deemed necessary, bronchoscopy must be performed using an ultrathin flexible scope under topical local anesthesia in an operating room with an experienced surgical team prepared for emergency surgical airway access.
• Laboratory Investigations: Non-specific systemic inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are elevated in over 80% of active flares and correlate with disease activity. Complete blood count typically shows a normocytic normochromic anemia of chronic disease or reactive leukocytosis. Autoantibody screening reveals circulating anti-type II collagen antibodies in 30% to 50% during acute chondritis. Testing for ANA, rheumatoid factor, and ANCA (anti-proteinase-3 and anti-myeloperoxidase) is necessary to evaluate for rheumatologic overlap syndromes.
• Genetic Testing for VEXAS Syndrome: In older male patients presenting with refractory chondritis, systemic fevers, macrocytic anemia, or bone marrow vacuoles, peripheral blood DNA sequencing for somatic mutations in the UBA1 gene should be performed.
• Cartilage Biopsy Indications & Hazards: Diagnostic cartilage biopsy is rarely indicated and should be avoided whenever clinical diagnostic criteria are fulfilled. Biopsy is reserved exclusively for atypical or isolated presentations where differential diagnoses (e.g., invasive fungal infection, mycobacterial chondritis, granulomatosis with polyangiitis, or lymphoma) cannot be excluded. If required, biopsy should be taken from the external ear pinna (antihelix or conchal cartilage). Histology demonstrates loss of basophilic matrix staining, perichondrial infiltration of lymphocytes and plasma cells, chondrocyte pyknosis, and fibrous replacement. Pitfall: Biopsy carries substantial clinical morbidity, frequently provoking persistent non-healing ulcers, secondary bacterial perichondritis, and permanent ear deformation.

7. Classification

Because there are no pathognomonic laboratory biomarkers, classification and diagnosis rely upon validated clinical diagnostic criteria systems that systematically aggregate anatomical chondritis sites and extra-cartilaginous manifestations.

In modern clinical practice, the Damiani & Levine and Michet criteria are the primary validated classification tools. They achieve over 90% diagnostic sensitivity and specificity without subjecting patients to the morbidity of invasive cartilage biopsy.

8. Treatment

Management of relapsing polychondritis requires a risk-stratified, interdisciplinary strategy that pairs medical immunosuppression with proactive airway protection and definitive cardiovascular intervention.

Medical / Nonoperative

Mild or Limited Cartilaginous Disease: First-line therapy for isolated auricular, nasal, or articular flares centers on symptomatic anti-inflammatory control:

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Effective initial regimens include indomethacin (50 mg three times daily), naproxen (500 mg twice daily), or celecoxib (200 mg twice daily).
• Dapsone: Administered at 25 to 100 mg daily; highly effective for cutaneous, auricular, and mild articular manifestations. Mandatory baseline testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency is required prior to initiation to prevent severe hemolytic anemia, alongside regular monitoring of complete blood counts for methemoglobinemia.
• Colchicine: Administered at 0.6 mg once or twice daily as an adjunct for mild chondral flares and joint symptoms.
• Low- to Moderate-Dose Oral Corticosteroids: Prednisone (15 to 30 mg daily; 0.25 to 0.5 mg/kg/day) for flares unresponsive to NSAIDs, tapered over 2 to 4 weeks upon symptom resolution.

Severe or Organ-Threatening Disease: Laryngotracheobronchial chondritis, necrotizing scleritis, aortic insufficiency, systemic vasculitis, or glomerulonephritis mandate immediate aggressive immunosuppressive therapy:

• High-Dose Systemic Corticosteroids: Oral prednisone (1 mg/kg/day, maximum 60 to 80 mg daily). For acute airway obstruction, sight-threatening scleritis, or acute heart block, intravenous pulse methylprednisolone (1000 mg daily for 3 consecutive days) is administered immediately.
• Conventional Synthetic DMARDs (csDMARDs): Initiated early to achieve steroid-sparing disease control: methotrexate (15 to 25 mg once weekly subcutaneously or orally with daily folic acid), azathioprine (2.0 to 2.5 mg/kg/day, guided by TPMT testing), or mycophenolate mofetil (1000 to 1500 mg twice daily). Intravenous pulsed cyclophosphamide (0.5 to 0.75 g/m2 monthly) is reserved for severe necrotizing systemic vasculitis or crescentic glomerulonephritis.
• Biologic DMARDs (bDMARDs) and Targeted Synthetics: Indicated for disease refractory to corticosteroids and csDMARDs, or for primary organ-threatening airway or vascular involvement. Anti-TNF-alpha agents (infliximab 5 to 10 mg/kg IV or adalimumab 40 mg SC every 2 weeks) are highly effective for articular and ocular inflammation. The interleukin-6 (IL-6) receptor antagonist tocilizumab (8 mg/kg IV monthly or 162 mg SC weekly) has demonstrated superior efficacy in arresting progressive tracheobronchial chondritis and resolving systemic inflammatory flares in steroid-refractory patients. Rituximab (1000 mg IV on days 1 and 15) is utilized for refractory vasculitis, and Janus kinase (JAK) inhibitors (tofacitinib or upadacitinib) are emerging options for refractory cases and VEXAS overlap.
• Supportive Prophylaxis: Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole (one double-strength tablet three times weekly) is mandatory during intensive immunosuppression, accompanied by bone-protective therapy with bisphosphonates, calcium, and vitamin D.

Operative / Interventional

The primary goals of interventional and surgical management in relapsing polychondritis are securing airway patency, preventing catastrophic asphyxiation, repairing life-threatening aortic root pathology, and reconstructing facial anatomy once systemic disease is fully quiescent.

Airway Management & Tracheostomy:

• Emergency and Elective Tracheostomy: Indicated for critical upper airway obstruction secondary to severe subglottic stenosis or cervical tracheomalacia. Surgical Pearl: Surgeons must utilize an extra-long, flexible, reinforced, or custom adjustable-flange tracheostomy cannula. Standard short tracheostomy tubes often terminate directly at or above the collapsed malacic segment, provoking immediate obstruction, mucosal ulceration, or fatal dynamic occlusion.
• Continuous Positive Airway Pressure (CPAP / BiPAP): Serves as a non-invasive “pneumatic stent”, generating continuous positive intraluminal pressure that counteracts dynamic expiratory collapse during sleep and acute inflammatory episodes, often avoiding or deferring invasive mechanical instrumentation.
• Tracheobronchial Stenting: The deployment of silicone (Dumon) or covered self-expanding metallic stents (SEMS) in severe tracheobronchomalacia is fraught with complications (mucus impaction, stent migration, granulation tissue proliferation, and fatal vascular erosion). Stenting must be reserved strictly as a temporary bridge to immunosuppressive remission in extreme respiratory failure or for terminal palliation when surgical resection is anatomically unfeasible.

Cardiovascular Surgical Reconstruction:

• Ascending Aortic Aneurysm Repair & Aortic Valve Replacement: Required for aortic root aneurysms or severe aortic regurgitation. Typically executed via a composite valve-graft root replacement (Bentall procedure) or valve-sparing aortic root reconstruction. Surgical caution: Aortic tissues in relapsing polychondritis are fragile and prone to suture pull-through. Suture lines must be heavily reinforced with Teflon felt pledgets, and coronary ostial reimplantation requires meticulous handling to avoid catastrophic late perivalvular leaks or pseudoaneurysm formation.
• Permanent Pacemaker Implantation: Indicated for complete heart block secondary to destructive inflammation of the cardiac fibrous skeleton.

Facial and Skeletal Reconstruction:

• Rhinoplasty and Saddle Nose Deformity Reconstruction: Cartilaginous or bone grafting (utilizing autologous calvarial bone, iliac crest, or costochondral grafts) to reconstruct the nasal dorsum. Timing rule: Reconstructive surgery is strictly contraindicated during active or subclinical inflammation. Surgery must be deferred until the patient has achieved minimum 6 to 12 months of sustained clinical, serologic, and radiographic remission under immunosuppressive therapy to prevent graft resorption and wound failure.
• Tympanostomy Tube Placement: Ventilating tubes provide symptomatic relief and prevent conductive hearing loss in chronic Eustachian tube dysfunction with persistent serous otitis media.

Indications & Contraindications

Clear numerical thresholds dictate interventional decision-making:

• Airway Intervention Thresholds: Tracheostomy is indicated when fixed subglottic luminal stenosis exceeds 50% diameter reduction, or dynamic expiratory luminal collapse exceeds 70% with resting stridor, hypercapnic respiratory acidosis, or failure of non-invasive positive pressure ventilation.
• Aortic Root Resection Thresholds: Surgical repair of the ascending aorta is indicated when ascending aortic root diameter reaches or exceeds 50 mm (or 45 mm in the presence of severe aortic regurgitation, rapid expansion exceeding 5 mm/year, or family history of dissection).
• Aortic Valve Replacement Thresholds: Indicated for symptomatic severe aortic regurgitation (NYHA class II-IV) or asymptomatic severe aortic regurgitation with left ventricular end-systolic dimension (LVESD) > 50 mm (or > 25 mm/m2) or left ventricular ejection fraction (LVEF) <= 50%.
• Absolute Contraindication to Biopsy: Biopsy of actively inflamed nasal septal or auricular cartilage is contraindicated when clinical criteria are met; tissue trauma triggers secondary chondral liquefaction, non-healing ulceration, and permanent aesthetic deformity.
• Contraindication to Elective Facial Reconstruction: Reconstructive rhinoplasty is absolutely contraindicated in the presence of active clinical chondritis or elevated systemic inflammatory markers (CRP > 5 mg/L, ESR > 25 mm/hr); minimum 6 to 12 months of documented disease quiescence is mandatory.

9. Outcome

The clinical course and functional outcomes of patients with relapsing polychondritis have undergone dramatic positive transformation over the past three decades:

• Survival Metrics: Ten-year overall survival in contemporary cohorts exceeds 85% to 90%, representing a profound improvement over historical survival benchmarks (55% at 10 years in the 1986 Michet Mayo Clinic series). This survival advantage is directly attributed to earlier diagnosis, avoidance of routine invasive cartilage biopsy, routine dynamic thoracic CT surveillance, modern intensive care airway protocols, and aggressive deployment of biologic DMARDs (anti-TNF and anti-IL-6 therapies).
• Relapsing Polychondritis Disease Activity Index (RPDAI): Developed and validated by the French Relapsing Polychondritis Study Group, the RPDAI is the primary standardized instrument for tracking disease activity. It comprises 27 clinical items with weighted scores ranging from 0 to 269: a score below 20 reflects inactive disease or remission; a score of 20 to 39 reflects moderate disease flare; and a score of 40 or greater indicates severe, organ-threatening flare requiring immediate therapeutic escalation.
• Relapsing Polychondritis Damage Index (RPDI): Measures irreversible cumulative structural organ damage across 8 physiological domains (ear, nose, eye, larynx/trachea, vascular, joint, central nervous system, and renal). Progressive accrual of RPDI points correlates directly with long-term functional impairment and secondary mortality risk.
• Long-Term Morbidity & Functional Sequelae: Despite improved survival curves, long-term functional morbidity remains substantial: permanent tracheostomy dependence occurs in 10% to 15% of patients with extensive dynamic tracheobronchomalacia; permanent sensorineural hearing loss occurs in 15% to 20%; saddle nose deformity develops in 25% to 30%; severe vision loss secondary to necrotizing scleritis occurs in 5% to 10%; and high rates of avascular necrosis of the femoral head (10% to 15%) occur secondary to prolonged high-dose corticosteroid exposure.

10. Complications

Complications in relapsing polychondritis arise from either progressive cartilaginous destruction, great vessel elastolysis, or prolonged systemic immunosuppressive toxicity.

11. Pearls and Pitfalls

Mastery in diagnosing and managing relapsing polychondritis relies upon distinguishing characteristic clinical signs and anticipating severe airway and vascular pitfalls:

• Pearl: The Lobule-Sparing Axiom: In any patient presenting with an acutely red, swollen, exquisitely tender ear, always inspect and palpate the earlobe. The non-cartilaginous lobule is strictly spared in relapsing polychondritis. If the lobule is erythematous, edematous, or indurated, the diagnosis is infectious cellulitis, erysipelas, or contact dermatitis.
• Pearl: Mandatory Dynamic Expiratory Thoracic Imaging: Never rely on a standard static inspiratory chest CT to rule out airway involvement. Cartilaginous destruction produces dynamic expiratory collapse that can be completely invisible on inspiratory scans. Always order paired inspiratory and dynamic end-expiratory low-dose HRCT of the thorax.
• Pearl: CPAP as a Non-Invasive Pneumatic Stent: When a patient with tracheomalacia presents with acute exertional or nocturnal dyspnea, initiate continuous positive airway pressure (CPAP or BiPAP) immediately. Intraluminal positive pressure splints the compliant, collapsing tracheal walls, rapidly reversing dynamic obstruction while systemic immunosuppressive therapy takes effect.
• Pearl: Teflon-Pledgeted Sutures in Aortic Reconstruction: In patients undergoing surgical repair of an ascending aortic aneurysm or aortic valve replacement, surgeons must reinforce all suture lines with deep Teflon felt pledgets. Fragile, proteoglycan-depleted aortic tissue provides poor suture holding capacity, predisposing to catastrophic late perivalvular leaks and pseudoaneurysm formation.
• Pearl: Screen Older Men for VEXAS Syndrome: In male patients over 50 years of age presenting with treatment-refractory relapsing polychondritis, recurrent fevers, macrocytic anemia, or bone marrow vacuoles, always perform peripheral blood genetic sequencing for somatic mutations in the UBA1 gene.
• Pitfall: Blind or Emergent Orotracheal Intubation: Never perform emergency blind orotracheal intubation with standard stylets or oversized endotracheal tubes in a patient with relapsing polychondritis presenting in acute stridor. The inflamed, malacic subglottic mucosa and softened tracheal rings can tear, avulse, or completely collapse upon contact. Always perform awake fiberoptic intubation with an experienced ENT surgeon scrubbed at the bedside prepared for immediate surgical airway access.
• Pitfall: Performing Routine Diagnostic Cartilage Biopsies: Do not perform an invasive cartilage biopsy of the ear or nose when standard clinical criteria (McAdam, Damiani-Levine, or Michet) are fulfilled. Biopsy rarely changes clinical management and frequently triggers secondary bacterial perichondritis, chronic non-healing ulceration, and permanent aesthetic deformity.
• Pitfall: Misdiagnosing Airway Involvement as Refractory Adult-Onset Asthma: Patients presenting with hoarseness, chronic cough, and wheezing that fails to respond to inhaled bronchodilators and inhaled corticosteroids should never be casually dismissed as having severe asthma. Always obtain flow-volume loops and dynamic airway CT to evaluate for fixed or variable upper airway obstruction.
• Pitfall: Premature Reconstructive Rhinoplasty: Performing nasal septal reconstruction or cartilage grafting during active or subclinical systemic disease guarantees graft resorption, extrusion, and catastrophic dorsal collapse. Ensure at least 6 to 12 months of documented disease quiescence prior to elective reconstruction.
• Pitfall: Using Standard Short Tracheostomy Cannulas: Inserting a standard-length tracheostomy tube in a patient with diffuse tracheomalacia frequently results in the tube tip abutting or sitting immediately above the collapsed malacic segment, precipitating acute complete obstruction. Always utilize an extra-long, flexible, reinforced, or custom adjustable-flange tracheostomy cannula.

12. Controversy

Several clinical domains in relapsing polychondritis remain subject to active debate and investigation:

Tracheobronchial Stenting vs. Conservative Pneumatic Splinting and Biologics: The utility and safety of endobronchial stenting in severe tracheobronchomalacia remain intensely controversial. While silicone (Dumon) or covered self-expanding metallic stents (SEMS) provide immediate mechanical scaffolding, long-term complication rates exceed 60% to 70%, including severe granulation tissue obstruction, stent migration, purulent bacterial colonization, and fatal erosion into major mediastinal vessels. Modern multidisciplinary consensus increasingly favors avoiding stenting whenever possible, utilizing non-invasive CPAP pneumatic stenting combined with aggressive biologic DMARD escalation (tocilizumab or infliximab) to halt chondrolysis, reserving stents strictly as a temporary bridge in acute respiratory failure or for terminal palliation.

Mandatory Biopsy vs. Pure Clinical Diagnostic Scoring: The historical mandate for histopathologic confirmation (McAdam 1976) has been largely supplanted by the Damiani & Levine and Michet criteria, which demonstrate over 90% diagnostic accuracy based on clinical features alone. Many experts argue that biopsy introduces unacceptable risks of cartilage necrosis and permanent deformity without adding diagnostic certainty. Conversely, some clinicians maintain that biopsy remains necessary in atypical, mono-symptomatic, or pediatric presentations to definitively exclude mimickers such as lymphoma, granulomatosis with polyangiitis, and deep fungal infections.

Biologic DMARD Selection and Sequencing: The comparative efficacy of anti-TNF agents (infliximab, adalimumab) versus interleukin-6 receptor antagonists (tocilizumab) or Janus kinase (JAK) inhibitors remains an area of active debate due to the lack of prospective randomized head-to-head clinical trials. While anti-TNF agents possess the largest registry dataset for articular and ocular inflammation, observational cohorts suggest that tocilizumab provides superior control of destructive tracheobronchial chondritis and systemic inflammatory flares. Determining whether tocilizumab should be deployed as first-line biologic therapy for all patients with respiratory involvement remains an active clinical question.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Petitdemange A, Sztejkowski C, Damian L et al. Treatment of relapsing polychondritis: a systematic review. Clin Exp Rheumatol. 2022. doi:10.55563/clinexprheumatol/h9gq1o [Level I: Systematic Review / Meta-Analysis]
• Montero ML, Panda RM, Palacios VJ et al. Systematic Literature Review of the Presentation and Management of Pediatric Relapsing Polychondritis. Ann Otol Rhinol Laryngol. 2024. doi:10.1177/00034894241275474 [Level I: Systematic Review / Meta-Analysis]
• Belot A, Duquesne A, Job-Deslandre C et al. Pediatric-onset relapsing polychondritis: case series and systematic review. J Pediatr. 2010. doi:10.1016/j.jpeds.2009.09.045 [Level I: Systematic Review / Meta-Analysis]
• Borgia F, Giuffrida R, Guarneri F et al. Relapsing Polychondritis: An Updated Review. Biomedicines. 2018. doi:10.3390/biomedicines6030084 [Level IV: Clinical Case Series / Cohort Study]
• Michet CJ Jr, McKenna CH, Luthra HS et al. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986. doi:10.7326/0003-4819-104-1-74 [Level IV: Clinical Case Series / Cohort Study]

15. Master Class Pro-Tip

When evaluating a patient with suspected or confirmed relapsing polychondritis presenting with respiratory symptoms, never be falsely reassured by a normal static inspiratory chest radiograph or conventional CT scan. Tracheobronchial chondromalacia is fundamentally a dynamic expiratory disorder. Always order paired inspiratory and dynamic end-expiratory high-resolution CT of the thorax alongside formal pulmonary function testing with complete flow-volume loops. If acute airway distress supervenes, avoid emergency blind endotracheal intubation, which can sheer friable subglottic mucosa and precipitate catastrophic, complete distal tracheal collapse. Immediately place the patient on continuous positive airway pressure (CPAP or BiPAP) to establish non-invasive pneumatic stenting, initiate high-dose intravenous methylprednisolone pulse therapy, and perform any necessary airway instrumentation awake under flexible fiberoptic guidance with an otolaryngologist scrubbed at the bedside equipped with an extra-long, custom adjustable-flange tracheostomy cannula.

Master Class Clinical Pearl: Relapsing Polychondritis